The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Outcomes following brexucabtagene autoleucel administered as an FDA-approved therapy for adults with relapsed/refractory B-ALL.
 
Gregory Roloff
No Relationships to Disclose
 
Rawan Faramand
Research Funding - Kite, a Gilead company (Inst); Novartis (Inst)
 
Ibrahim Aldoss
Consulting or Advisory Role - Abbvie; Agios; Amgen; Autolus; Jazz Pharmaceuticals; Kite/Gilead; Pfizer; SOBI
Research Funding - Abbvie (Inst); MacroGenics (Inst)
 
Noam Edward Kopmar
No Relationships to Disclose
 
Marc Schwartz
Consulting or Advisory Role - Novartis
 
Simone E. Dekker
No Relationships to Disclose
 
Chenyu Lin
No Relationships to Disclose
 
Sean Tracy
No Relationships to Disclose
 
Santiago Mercadal Vilchez
No Relationships to Disclose
 
Kaitlyn Dykes
No Relationships to Disclose
 
Timothy O'Connor
No Relationships to Disclose
 
Mohamed Amin Ahmed
No Relationships to Disclose
 
Vishal K Gupta
No Relationships to Disclose
 
Abdullah Ladha
Honoraria - CTI BioPharma Corp
Consulting or Advisory Role - Kite, a Gilead Company
 
Stephanie Tsai
Consulting or Advisory Role - Bristol-Myers Squibb; Jazz Pharmaceuticals
 
Jessica Taft Leonard
Consulting or Advisory Role - Adaptive Biotechnologies; Kite/Gilead; Pfizer; Takeda
Travel, Accommodations, Expenses - Adaptive Biotechnologies
(OPTIONAL) Uncompensated Relationships - Abbvie; Amgen; Kite/Gilead
 
Ahmed Galal
Speakers' Bureau - Incyte; Kite/Gilead; Seagen
Research Funding - Crispr Therapeutics (Inst); Iovance Biotherapeutics (Inst)
 
Ryan Daniel Cassaday
Employment - Seagen (I)
Stock and Other Ownership Interests - Seagen (I)
Honoraria - Kite, a Gilead company; Pfizer
Consulting or Advisory Role - Amgen; Jazz Pharmaceuticals; Kite/Gilead; Pfizer
Research Funding - Amgen (Inst); Incyte (Inst); Kite, a Gilead company (Inst); Pfizer; SERVIER (Inst); Vanda Pharmaceuticals
Travel, Accommodations, Expenses - Kite, a Gilead company
Other Relationship - Autolus; Pepromene
 
Bijal D. Shah
Honoraria - BeiGene; Gilead Sciences; Pharmacyclics/Janssen; Spectrum/Acrotech
Consulting or Advisory Role - Adaptive Biotechnologies; Amgen; Autolus; Bristol-Myers Squibb/Celgene; Century Therapeutics; Deciphera; Jazz Pharmaceuticals; Kite, a Gilead company; Lilly; Novartis; Pepromene; Pfizer; Pfizer; Precision Biosciences
Research Funding - Incyte; Jazz Pharmaceuticals (Inst); Kite/Gilead (Inst); SERVIER (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Celgene; Janssen; Kite, a Gilead company; Novartis; Pfizer; Seagen; Stemline Therapeutics
 
Lori S. Muffly
Stock and Other Ownership Interests - Corvus Pharmaceuticals
Honoraria - UpToDate
Consulting or Advisory Role - Amgen; Astellas Pharma; CTI BioPharma Corp; Kite, a Gilead company; Medexus Pharmaceuticals
Research Funding - Adaptive Biotechnologies; Astellas Pharma; Bristol-Myers Squibb.; Jasper Therapeutics; Kite, a Gilead company